Laura M. Kidd Cordova

Healthcare

• Represented pharmacy chain in DOJ joint criminal and civil False Claims Act (FCA) investigation arising from qui tam complaint alleging improperly obtained prior authorizations and violations of the Anti-Kickback Statute
• Represented trade organization in DOJ joint criminal and civil FCA investigation related to health insurance premium assistance programs
• Represented nonprofit in DOJ FCA investigation related to pharmaceutical patient assistance programs
• Represented national hospital system in DOJ FCA investigation arising from qui tam actions filed in multiple districts alleging improper diagnosis of patients
• Represented global healthcare company in DOJ FCA investigation related to generic drug pricing
• Represented executive in DOJ FCA investigation related to drug pricing and alleged Anti-Kickback Statute violations
• Represented pharmaceutical sales representative in DOJ FCA investigation related to alleged off-label marketing and violations of the Anti-Kickback Statute
• Conducted internal investigation for national hospital system in response to internal whistleblower allegations of Anti-Kickback Statute violations and improper patient inducement, and advised system regarding disclosure obligations and potential FCA liability
• Conducted internal investigation related to billing code errors, and advised regional hospital system regarding disclosure obligations and potential FCA liability

Government Contracts

• Represented Fortune 20 healthcare company in DOJ FCA investigation arising from qui tam complaint alleging company conspired with service-disabled veteran-owned small businesses to fraudulently obtain Veterans Affairs supply contracts
• Represented contractor in Defense Criminal Investigative Service (DCIS) investigation related to labor cost reporting
• Represented Fortune 50 government contractor in DCIS investigation regarding compliance with federal government contract cybersecurity requirements
• Represented financial services company in DOJ FCA investigation of allegations that company conspired with construction company to commit fraud on the Small Business Administration’s 8(a) program
• Conducted internal investigation and advised healthcare products distribution company regarding compliance, disclosure obligations, and potential FCA liability related to various federal government contracts, including pricing obligations, the Buy American Act, and the Trade Agreements Act
• Conducted internal investigation and advised health plan regarding compliance, disclosure obligations, and potential FCA liability related to California state contract requirements

Securities Fraud and Other White Collar Matters

• Represented hospital system in DOJ and state Attorney General investigations related to tax credits
• Conducted internal investigation for Fortune 10 company related to allegations of improper accounting practices at a South American subsidiary
• Conducted internal investigation and represented global agricultural commodity trading company in criminal DOJ and USDA investigation related to imported agricultural products
• Represented former CEO in DOJ and SEC securities fraud investigations and related derivative and class actions alleging accounting fraud
• Represented foreign-exchange trader charged with wire fraud for allegedly “front-running” a foreign exchange transaction

• The Best Lawyers in America (Woodward/White Inc.), Commercial Litigation, 2023
• Lawdragon 500 Leading Litigators in America, 2022
• Washington DC Super Lawyer, Super Lawyers by Thomson Reuters, 2020-2021
• Assistant Attorney General’s Award for Distinguished Service, 2015
• Health and Human Services Inspector General’s Award for Excellence in Fighting Fraud, Waste, and Abuse, 2016
• IRS Criminal Investigation’s Recognition for Outstanding Support of the IRS Criminal Investigation Mission, 2016
• FBI Director’s Certificate for Demonstrated Excellence in Successfully Prosecuting a Major Criminal Case, 2014

Publications

• “US Supreme Court to Decide Whether the Government Can Prove Knowledge When the Defendant’s Regulatory Interpretation Is “Objectively Reasonable”,” Jackson Walker Insights (January 2023)
• “U.S. Supreme Court to Decide Standard for DOJ Dismissal of Qui Tam Cases,” Jackson Walker Insights (June 2022)
• “What to Know About the Department of Justice’s Nationwide Crackdown on Healthcare Fraud,” Jackson Walker Insights (September 2021)
• “DOJ Moves to Dismiss 10 Kickback-Related False Claims Act Complaints Against Pharmaceutical Companies,” Pratt’s Government Contracting Law Report (April 2019)
• “DOJ Resets Bar for Corporate-Cooperation Credit and Shifts Emphasis in False Claims Act Cases from Individual Accountability to Monetary Recovery,” Westlaw Journal’s Government Contract (January 2019)
• “Are Government and Health Care Contracts the Exception That Swallows the Brand Memo’s Rule on FCA Enforcement?” Westlaw Journal’s Government Contract (October 2018)
• “Department of Justice Leadership Previews Reforms to False Claims Act Enforcement: Significant Incentives for Cooperation and Strong Compliance,” Pratt’s Government Contracting Law Report (October 2018)

Speaking Engagements

• Moderator, “Litigation Challenges in Procurement Fraud Matters,” 10th Annual False Claims and Qui Tam Trial Institute (April 2022)
• “Healthcare Enforcement and Why Effective Corporate Compliance Matters,” International Association of Defense Counsel (IADC) 2020 Midyear Meeting (February 2020)
• “Healthcare Fraud Enforcement and Corporate Compliance,” 2019 National Asian Pacific American Bar Association (NAPABA) Convention (November 2019)
• “801 Recent Developments in Individual Criminal and Civil Culpability,” Health Care Compliance Association’s (HCCA) 4th Annual Healthcare Enforcement Compliance Conference (November 2018)
• “Developments in Individual Criminal and Civil Culpability Post-Yates Memorandum,” American Health Law Association (AHLA) Fraud and Compliance Forum (September 2018)
• “Deep-Dive into Reverse False Claims: Preparing for the Future of False Claims for MCOs,” American Conference Institute (ACI) Managed Care Disputes and Litigation Conference (May 2018)
• “Pricing Governance and Anticipating Fraud and Abuse Risks in Light of the Current Pricing Debate,” American Conference Institute (ACI) 18th Annual Conference on Fraud and Abuse (March 2018)
• “Expectations of the DOJ,” Society of Corporate Compliance and Ethics (SCCE) Boston Regional Compliance & Ethics Conference (March 2017)
• “Developments with the False Claims Act and Qui Tam Enforcement in Light of the Escobar Decision,” American Conference Institute (ACI) 17th Annual Conference on Fraud and Abuse in the Sale and Marketing of Drugs, Devices, and Medical Technology (March 2017)
• “A Spotlight on Recent Trends in Enforcement,” CBI’s 5th Annual Compliance Monitoring Forum (February 2017)
• “Program Effectiveness – What’s the Government Looking for in Your Compliance Program?” American Health Law Association (AHLA) Fraud and Compliance Forum (October 2016)
• “Understand Trends in Recent Enforcement Targets,” CBI’s 10th Annual Forum on Transparency and Aggregate Spend (Aug. 2016)
• “From the Boardroom to the Big House? How Corporate Compliance and Government Regulations Keep You Safe,” Memphis Bar Association (July 2016)
• “U.S. Department of Justice Healthcare Compliance Update,” Global Healthcare 10th International Pharmaceutical Compliance Congress (May 2016)
• “U.S. Healthcare Fraud Enforcement,” CBI’s 13th Annual Pharmaceutical Compliance Congress (April 2016)
• “Emerging Enforcement Trends in Healthcare,” American Bar Association (ABA) 30th Annual National Institute on White Collar Crime (March 2016)

In the News

• “Ex-Fed. Health Care Prosecutor Laura Cordova Discusses Whistleblower Suits, Their Future Under Trump,” Corporate Counsel (March 2017)